Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
P/S ratio for Madrigal Pharmaceuticals, Inc. (MDGL)
P/S ratio as of 2023: 0.00
According to Madrigal Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 0.00.
P/S ratio history for Madrigal Pharmaceuticals, Inc. from 2001 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 0.00 |
| 2022 | 0.00 |
| 2021 | 0.00 |
| 2020 | 0.00 |
| 2019 | 0.00 |
| 2018 | 0.00 |
| 2017 | 0.00 |
| 2016 | 0.00 |
| 2015 | 0.00 |
| 2014 | 0.00 |
| 2013 | 0.00 |
| 2012 | 3645.47 |
| 2011 | 29.06 |
| 2010 | 16.69 |
| 2009 | 1.19 |
| 2008 | 78.95 |
| 2007 | 292.76 |
| 2006 | 0.00 |
| 2005 | 0.00 |
| 2004 | 982.75 |
| 2003 | 152.33 |
| 2002 | 0.00 |
| 2001 | 0.00 |